The Government of Chhattisgarh has accelerated plans to establish a dedicated Pharmaceutical and Biotechnology Park as part of its broader strategy to attract large-scale investments in the life sciences sector. The proposed park spanning up to 500 acres in a strategically selected industrial corridor will offer plug-and-play infrastructure, fiscal incentives, streamlined approvals, and R&D support facilities to position the state as a competitive destination for domestic and international pharma and biotech companies.
Glimpse:
Announced during a high-level industry roundtable on January 17, 2026, the Chhattisgarh Pharma Park will target manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms, biopharmaceuticals, vaccines, and medical devices. The state is offering long-term land leases at concessional rates, power subsidies, stamp duty exemptions, and capital investment subsidies up to 25%, alongside single-window clearances and dedicated skill development programmes. The initiative aligns with the national PLI scheme and aims to generate thousands of direct and indirect jobs while reducing India’s dependence on imported APIs and biologics.
Chhattisgarh is intensifying efforts to emerge as a significant player in India’s pharmaceutical and biotechnology landscape with the formal announcement of a dedicated Pharma & Biotech Park. Chief Minister Vishnu Deo Sai, addressing a gathering of industry leaders, state officials, and potential investors on January 17, 2026, described the proposed park as “a transformative step toward building a self-reliant, high-growth life sciences ecosystem in the state.”
The park is planned as an integrated industrial zone with ready-to-use infrastructure: common effluent treatment plants, dedicated power substations, high-speed logistics connectivity, quality control laboratories, R&D incubation centres, and regulatory facilitation cells. Officials have shortlisted multiple sites along key industrial corridors with proximity to major highways, rail networks, and upcoming airport expansions to ensure seamless access to domestic and export markets.
Incentives under consideration include:
- Long-term land allotment at significantly concessional rates
- Capital investment subsidy of up to 25% on eligible project costs
- Complete exemption from stamp duty and registration fees
- Power tariff subsidies for the first five to seven years
- Interest subsidy on term loans
- Reimbursement of SGST and other state-level taxes for a defined period
- Fast-track environmental and regulatory approvals through a single-window mechanism
The state is also committing to workforce development through partnerships with local engineering colleges, ITIs, and national skill councils to create a pipeline of trained manpower in pharmaceutical manufacturing, quality assurance, regulatory affairs, and bioprocessing.
The Chhattisgarh Pharma Park initiative aligns closely with national priorities under the Production Linked Incentive (PLI) scheme for pharmaceuticals, bulk drugs, and medical devices. State officials highlighted that Chhattisgarh’s abundant availability of land, relatively low operational costs compared to western and southern industrial hubs, and improving logistics connectivity make it an attractive alternative for companies looking to diversify manufacturing footprints.
Early interest has already been expressed by domestic players in APIs, generics, and biologics, as well as international firms exploring India as a cost-effective, high-quality manufacturing base amid ongoing global supply chain rebalancing. The government expects the first anchor tenants to be finalised within 12–18 months, with initial production commencing by 2028.
The announcement reflects Chhattisgarh’s broader economic diversification strategy, moving beyond its traditional reliance on mining and steel to build knowledge-based industries with high employment multipliers and export potential.
“Chhattisgarh is open for business in pharmaceuticals and biotechnology. With world-class infrastructure, competitive incentives, and a commitment to ease of doing business, we are ready to partner with industry to build a vibrant life sciences ecosystem that creates jobs and drives inclusive growth.”
By
HB Team
